A research team led by Associate Research Fellow Joyce Jean Lu at Academia Sinica has developed an innovative cell therapy technique that directly converts human fibroblasts into retinal precursor cells using small molecule drugs. This method boasts a conversion efficiency of 42.8% in just five days, and, more importantly, it does not require genetic modification or viral vectors, significantly reducing treatment risks.
Blindness not only impacts patients' quality of life but also takes a heavy toll on their mental well-being. According to the World Health Organization, about 25% of incurable blindness worldwide is caused by photoreceptor cell degeneration. Current treatments, such as stem cell transplants and gene therapy, face challenges including limited cell availability, complex techniques, and high costs. Therefore, the development of safe, effective, and affordable therapies is urgently needed.
Small Molecule Reprogramming: Efficient, Safe, and Cost-Effective
At the heart of this new therapy is a combination of six small molecule drugs (referred to as 6C), which act as signaling molecules to either activate or inhibit specific transcription factors and regulatory proteins. This process finely controls gene expression, leading human fibroblasts to express genes characteristic of retinal precursor cells, ultimately converting them into such cells.
This technique offers several key advantages:
High Efficiency and Low Cost: The conversion efficiency is as high as 42.8%, with the process taking only five days. The use of small molecules as conversion factors helps reduce the costs of cell processing, lessening the financial burden on patients.
Low Risk of Tumor Formation and No Genetic or Viral Interventions: The use of low-proliferation precursor cells minimizes the risk of side effects such as tumor formation. Additionally, the conversion process does not involve genetic modification or viral vectors, enhancing the safety and reliability of the treatment.
Simple and Efficient Treatment Process: The treatment is straightforward and highly efficient. After the injection of the converted retinal precursor cells into the patient’s eye, the cells are absorbed and differentiate, completing the treatment. This not only reduces the burden on patients but also increases the efficiency and convenience of the procedure.
Proven Effectiveness in Animal Trials: Animal studies have demonstrated that transplanted retinal precursor cells can significantly improve visual function, with the potential to restore both black-and-white and color vision, offering patients a more comprehensive visual experience.
A New Hope for Blindness: Revolutionary Cell Therapy
Associate Research Fellow Joyce Jean Lu highlighted that this technique shows significant promise in treating diseases caused by photoreceptor degeneration. It has particularly high potential for conditions such as macular degeneration, diabetic retinopathy, and retinitis pigmentosa (night blindness). In the future, the team plans to collaborate with medical institutions and pharmaceutical companies to apply this technology in clinical cell therapy, providing new treatment options for patients suffering from photoreceptor degeneration. The team will also continue to optimize the technique to improve its therapeutic effects and explore its applications in other ophthalmic diseases.
This groundbreaking therapy offers a ray of hope for the treatment of blindness, bringing the possibility of restoring vision within reach for millions of patients worldwide.
Resource (mandarin): 揮別黑暗人生！小分子藥物治療感光細胞恢復彩色視覺
